The pcsk9 inhibitors are generally used in combination with statins, and only patients who are intolerant or contraindicated to statins can use pcsk9 inhibitors alone. China’s marketed pcsk9 inhibitors include iloyumab, which can be used in combination with the maximum tolerated dose of a statin to reduce the risk of cardiovascular events in patients with coronary heart disease, or in combination with a pure subtype of familial hypercholesterolemia. For those who cannot tolerate statins or have contraindications, iloyuzumab can be used alone. Adverse reactions to eloxizumab include nasopharyngitis, influenza, cough, upper respiratory tract infections, urinary tract infections, and dizziness, and it is contraindicated in those who are allergic to the product. Please select the appropriate medication regimen according to the patient’s condition under the guidance of a physician and adhere to the medication for a long period of time.